(Q35154543)

6 August 2017

1 reference

title

ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients? (English)

1 reference

6 August 2017

Luis M Ruilope

1

0 references

author name string

Julian Segura

series ordinal

2

1 reference

6 August 2017

Ernesto L Schiffrin

series ordinal

3

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

74-79

1 reference

The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Renal function: the Cinderella of cardiovascular risk profile

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Evolving strategies for renoprotection: diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Ongoing trials of angiotensin-converting enzyme inhibition: what they can tell us.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Dual renin-angiotensin system blockade at optimal doses for proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

A prospective comparison of four antihypertensive agents in daily clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations?

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Cardiovascular protection and blood pressure reduction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.016

21 January 2018

Identifiers

DOI

10.3317/JRAAS.2003.016

1 reference

release_symgokbna5ex3giagzza2azpem

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/symgokbna5ex3giagzza2azpem

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference